Substantial evidence supports that sodium-glucose cotransporter 2 inhibitors (SGLT-2i) and nonsteroidal mineralocorticoid receptor antagonists (nsMRAs) slow DKD progression when used alongside renin-angiotensin system inhibitors in T2DM patients. The gene discussed is NR3C2; the disease is diabetic kidney disease.